To examine the safety and efficacy of tofacitinib in subjects with active psoriatic arthritis who have previously had an inadequate response to at least one TNF inhibitor either due to lack of efficacy or an adverse event.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01882439?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
